Cargando…

Epithelial Signaling through the RUNX1/AKT Pathway: A New Therapeutic Target in Kidney Fibrosis

Detalles Bibliográficos
Autor principal:	Galichon, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020706/ https://www.ncbi.nlm.nih.gov/pubmed/29885863 http://dx.doi.org/10.1016/j.ebiom.2018.05.020

Ejemplares similares

Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?
por: Galichon, Pierre, et al.
Publicado: (2011)

Thymosin beta 4 is associated with RUNX2 expression through the Smad and Akt signaling pathways in mouse dental epithelial cells
por: SOMEYA, HIROTAKA, et al.
Publicado: (2015)

Treatment of keloids through Runx2 siRNA-induced inhibition of the PI3K/AKT signaling pathway
por: Lv, Wenchang, et al.
Publicado: (2021)

Modulating microRNAs as Novel Therapeutic Targets in Cardiac Fibrosis
por: Chen, Zhongxiu, et al.
Publicado: (2017)

Epigenetic changes during sepsis: on your marks!
por: Bataille, Aurélien, et al.
Publicado: (2015)

Cadherin 6 Is a New RUNX2 Target in TGF-β Signalling Pathway
por: Sancisi, Valentina, et al.
Publicado: (2013)

Revision of RUNX1 variant curation rules
por: Feurstein, Simone, et al.
Publicado: (2022)

New targets for new therapeutic approaches
por: François, Bruno
Publicado: (2014)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

Inhibition of microRNA‐149 protects against recurrent miscarriage through upregulating RUNX2 and activation of the PTEN/Akt signaling pathway
por: Wang, Peng, et al.
Publicado: (2020)

Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2?
por: Santamaria, Salvatore
Publicado: (2021)

A Breathe in Cystic Fibrosis Therapy: A New Therapeutic Endeavor for Cysteamine
por: De Stefano, Daniela, et al.
Publicado: (2015)

Cellular and Molecular Signaling as Targets for Cancer Vaccine Therapeutics
por: Wei, Wen-Chi, et al.
Publicado: (2022)

Periostin Facilitates the Epithelial-Mesenchymal Transition of Endometrial Epithelial Cells through ILK-Akt Signaling Pathway
por: Zheng, Qiao-mei, et al.
Publicado: (2016)

Translating Metabolic Reprogramming into New Targets for Kidney Cancer
por: Abu Aboud, Omran, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder
por: Kumar, Rakesh K
Publicado: (2002)

RUNX1: an emerging therapeutic target for cardiovascular disease
por: Riddell, Alexandra, et al.
Publicado: (2020)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Elucidation of Novel Therapeutic Targets for Acute Myeloid Leukemias with RUNX1-RUNX1T1 Fusion
por: Yun, Jae Won, et al.
Publicado: (2019)

Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities
por: Fu, Dongliao, et al.
Publicado: (2022)

Human glomerular transcriptome of diabetic kidneys: Can the podocyte cytoskeleton be a therapeutic target?
por: Maezawa, Yoshiro, et al.
Publicado: (2018)

RUNX1 regulates the proliferation and chemoresistance of colorectal cancer through the Hedgehog signaling pathway
por: Li, Qingyuan, et al.
Publicado: (2021)

Targeting the non-canonical AKT-FOXO3a axis: A potential therapeutic strategy for oral squamous cell carcinoma
por: Liu, Ying
Publicado: (2019)

RUNX1-Regulated Signaling Pathways in Ovarian Cancer
por: Chen, Yuanzhi, et al.
Publicado: (2023)

Targeting hypoxia in tumor: a new promising therapeutic strategy
por: Bosco, Maria Carla, et al.
Publicado: (2020)

Decoupling dedifferentiation and G(2)/M arrest in kidney fibrosis
por: Humphreys, Benjamin D.
Publicado: (2022)

RUNX2 as a promising therapeutic target for malignant tumors
por: Zhao, Weizhu, et al.
Publicado: (2021)

RUNX2-modifying enzymes: therapeutic targets for bone diseases
por: Kim, Woo-Jin, et al.
Publicado: (2020)

RUNX inhibitor suppresses graft‐versus‐host disease through targeting RUNX‐NFATC2 axis
por: Kubota, Hirohito, et al.
Publicado: (2021)

Signaling through Raf-1 in the Neovasculature and Target Validation by Nanoparticles
por: Wary, Kishore K
Publicado: (2003)

The RNA interference pathway: a new target for autoimmunity
por: Pruijn, Ger JM
Publicado: (2006)

Epithelial–mesenchymal transition is driven by transcriptional and post transcriptional modulations in COPD: implications for disease progression and new therapeutics
por: Eapen, Mathew Suji, et al.
Publicado: (2019)

Therapeutic Implications of Targeting AKT Signaling in Melanoma
por: Madhunapantula, SubbaRao V., et al.
Publicado: (2011)

Editorial: Molecular Mechanisms and New Therapeutic Targets in Epithelial to Mesenchymal Transition (EMT) and Fibrosis
por: Battistelli, Cecilia, et al.
Publicado: (2020)

Insulin resistance in the brain: A new therapeutic target for Alzheimer's disease
por: Umegaki, Hiroyuki
Publicado: (2013)

Phosphatidylserine trapped in the net: A new therapeutic target for the ischemic stroke?
por: Rodriguez Lucci, Federico, et al.
Publicado: (2020)

New insights into the pathogenesis and therapeutics of kidney fibrosis
por: Hou, Fan Fan, et al.
Publicado: (2014)

Energy metabolism pathways in breast cancer progression: The reprogramming, crosstalk, and potential therapeutic targets
por: Zheng, Xuewei, et al.
Publicado: (2022)

Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer
por: Wall, Jaclyn A., et al.
Publicado: (2020)

Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathway
por: West, Camilla, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1vs3m680cg62cpkb569d0e2p2i